State Street Corp Concert Pharmaceuticals, Inc. Transaction History

State Street Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.0 - $8.4 $0 - $1.18 Million	-140,898 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$4.34 - $5.84 $88,102 - $118,552	20,300 Added 16.83%	140,898 $822,000
Q3 2022 Nov 15, 2022	BUY	$4.27 - $7.2 $79,848 - $134,640	18,700 Added 18.35%	120,598 $808,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $6.36 $73,080 - $165,996	26,100 Added 34.43%	101,898 $429,000
Q1 2022 May 16, 2022	BUY	$2.73 - $3.94 $13,808 - $19,928	5,058 Added 7.15%	75,798 $255,000
Q3 2021 Nov 15, 2021	SELL	$3.17 - $4.15 $13,631 - $17,845	-4,300 Reduced 5.73%	70,740 $231,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $5.24 $1.49 Million - $2.07 Million	-394,415 Reduced 84.02%	75,040 $317,000
Q1 2021 May 17, 2021	SELL	$4.86 - $13.07 $112,426 - $302,348	-23,133 Reduced 4.7%	469,455 $2.34 Million
Q4 2020 Feb 16, 2021	SELL	$9.48 - $12.84 $17,689 - $23,959	-1,866 Reduced 0.38%	492,588 $6.23 Million
Q3 2020 Nov 10, 2020	BUY	$8.67 - $10.82 $84,489 - $105,440	9,745 Added 2.01%	494,454 $4.86 Million
Q2 2020 Aug 14, 2020	BUY	$7.8 - $11.52 $122,374 - $180,737	15,689 Added 3.35%	484,709 $4.82 Million
Q1 2020 May 11, 2020	BUY	$5.98 - $13.09 $2.8 Million - $6.14 Million	469,020 New	469,020 $4.15 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.